Henry Schein (NASDAQ:HSIC) Receives Outperform Rating from Barrington Research

Barrington Research reaffirmed their outperform rating on shares of Henry Schein (NASDAQ:HSIC) in a research report report published on Wednesday morning, Benzinga reports. They currently have a $82.00 price objective on the stock. Barrington Research also issued estimates for Henry Schein’s Q4 2024 earnings at $1.20 EPS, Q1 2025 earnings at $1.12 EPS, Q2 2025 earnings at $1.26 EPS, Q3 2025 earnings at $1.27 EPS, Q4 2025 earnings at $1.46 EPS, FY2025 earnings at $5.12 EPS and FY2026 earnings at $5.80 EPS.

A number of other brokerages also recently commented on HSIC. Robert W. Baird lowered their price objective on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. StockNews.com downgraded shares of Henry Schein from a “hold” rating to a “sell” rating in a research report on Wednesday, October 30th. Evercore ISI boosted their price objective on shares of Henry Schein from $70.00 to $74.00 and gave the company an “in-line” rating in a research report on Tuesday, October 8th. JPMorgan Chase & Co. lowered their price objective on shares of Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. Finally, Baird R W raised shares of Henry Schein from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 22nd. One analyst has rated the stock with a sell rating, six have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Henry Schein presently has a consensus rating of “Hold” and a consensus target price of $77.50.

Henry Schein Price Performance

Shares of NASDAQ HSIC traded down $1.09 during midday trading on Wednesday, reaching $68.92. The company’s stock had a trading volume of 141,276 shares, compared to its average volume of 1,350,931. The company has a current ratio of 1.55, a quick ratio of 0.90 and a debt-to-equity ratio of 0.46. The company has a 50 day moving average price of $70.59 and a 200 day moving average price of $69.78. Henry Schein has a one year low of $62.12 and a one year high of $82.63. The company has a market cap of $8.73 billion, a price-to-earnings ratio of 25.93, a price-to-earnings-growth ratio of 2.08 and a beta of 0.87.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, November 5th. The company reported $1.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.17 by $0.05. Henry Schein had a net margin of 2.82% and a return on equity of 13.19%. The business had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.24 billion. During the same quarter in the previous year, the business earned $1.32 earnings per share. The firm’s revenue was up .4% compared to the same quarter last year. On average, equities research analysts expect that Henry Schein will post 4.74 EPS for the current year.

Insider Activity at Henry Schein

In related news, SVP Lorelei Mcglynn sold 21,035 shares of the company’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the completion of the transaction, the senior vice president now directly owns 71,833 shares in the company, valued at $4,978,026.90. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.14% of the company’s stock.

Hedge Funds Weigh In On Henry Schein

Hedge funds have recently made changes to their positions in the business. UniSuper Management Pty Ltd raised its stake in shares of Henry Schein by 611.8% in the 1st quarter. UniSuper Management Pty Ltd now owns 13,695 shares of the company’s stock valued at $1,034,000 after buying an additional 11,771 shares in the last quarter. Envestnet Portfolio Solutions Inc. raised its stake in shares of Henry Schein by 64.2% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 41,558 shares of the company’s stock valued at $3,138,000 after buying an additional 16,241 shares in the last quarter. Thompson Siegel & Walmsley LLC acquired a new position in shares of Henry Schein in the 2nd quarter valued at $46,683,000. Nordea Investment Management AB grew its holdings in shares of Henry Schein by 8.9% in the 1st quarter. Nordea Investment Management AB now owns 9,785 shares of the company’s stock worth $744,000 after purchasing an additional 798 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Henry Schein by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 15,432,001 shares of the company’s stock worth $1,165,425,000 after purchasing an additional 260,537 shares during the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.